- Home
- ABBV vs NVO Comparison
ABBV vs NVO Comparison
Compare ABBV & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABBV
- NVO
- Stock Information
- Founded
- ABBV 2012
- NVO 1923
- Country
- ABBV United States
- NVO Denmark
- Employees
- ABBV N/A
- NVO N/A
- Industry
- ABBV Biotechnology: Pharmaceutical Preparations
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABBV Health Care
- NVO Health Care
- Exchange
- ABBV Nasdaq
- NVO Nasdaq
- Market Cap
- ABBV 338.3B
- NVO 278.0B
- IPO Year
- ABBV N/A
- NVO N/A
- Fundamental
- Price
- ABBV $185.08
- NVO $69.14
- Analyst Decision
- ABBV Buy
- NVO Buy
- Analyst Count
- ABBV 22
- NVO 3
- Target Price
- ABBV $213.14
- NVO $112.00
- AVG Volume (30 Days)
- ABBV 6.1M
- NVO 9.2M
- Earning Date
- ABBV 07-31-2025
- NVO 08-06-2025
- Dividend Yield
- ABBV 3.53%
- NVO 1.71%
- EPS Growth
- ABBV N/A
- NVO 17.93
- EPS
- ABBV 2.34
- NVO 3.40
- Revenue
- ABBV $57,367,000,000.00
- NVO $43,922,211,349.00
- Revenue This Year
- ABBV $8.48
- NVO $18.59
- Revenue Next Year
- ABBV $8.19
- NVO $15.61
- P/E Ratio
- ABBV $79.32
- NVO $20.28
- Revenue Growth
- ABBV 5.45
- NVO 24.11
- 52 Week Low
- ABBV $163.52
- NVO $57.00
- 52 Week High
- ABBV $218.66
- NVO $145.99
- Technical
- Relative Strength Index (RSI)
- ABBV 43.37
- NVO 44.45
- Support Level
- ABBV $181.73
- NVO $66.87
- Resistance Level
- ABBV $188.99
- NVO $71.04
- Average True Range (ATR)
- ABBV 3.63
- NVO 1.51
- MACD
- ABBV -0.57
- NVO -1.15
- Stochastic Oscillator
- ABBV 14.33
- NVO 15.58
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.